IBRI IN THE NEWS: IBRI Researchers Find Opportunity to Repurpose Drugs for Type 1 Diabetes
More than 7% of Americans suffer from debilitating and, in some cases, life-threatening autoimmune diseases. With diagnoses on the rise, researchers continue the quest for more effective treatments and the...
IBRI RESEARCH PUBLISHED: Gene Expression Signatures of Target Tissues in Type 1 Diabetes, Lupus Erythematosus, Multiple Sclerosis, and Rheumatoid Arthritis
Abstract Autoimmune diseases are typically studied with a focus on the immune system, and less attention is paid to responses of target tissues exposed to the immune assault. We...
A New Approach to Study Autoimmune Diseases
Indianapolis, Ind. - A team of researchers led by the Indiana Biosciences Research Institute Diabetes Center’s Scientific Director Decio L. Eizirik, MD, PhD, has found that identifying new treatments for...
IBRI RESEARCH PUBLISHED: The RNA-binding Profile of the Splicing Factor SRSF6 in Immortalized Human Pancreatic ß-cells
Abstract In pancreatic β-cells, the expression of the splicing factor SRSF6 is regulated by GLIS3, a transcription factor encoded by a diabetes susceptibility gene. SRSF6 down-regulation promotes β-cell demise...
IBRI RESEARCH PUBLISHED: Persistent or Transient Human ß Cell Dysfunction Induced by Metabolic Stress: Specific Signatures and Shared Gene Expression with Type 2 Diabetes
Abstract Pancreatic β cell failure is key to type 2 diabetes (T2D) onset and progression. Here, we assess whether human β cell dysfunction induced by metabolic stress is reversible,...
IBRI RESEARCH PUBLISHED: Phenotypic Sexual Dimorphism in Response to Dietary Fat Manipulation in C57BL/6J Mice
Abstract Background : Obesity and the metabolic syndrome are increasingly prevalent in society and their complications and response to treatment exhibit sexual dimorphism. Mouse models of high fat diet-induced...
IBRI RESEARCH PUBLISHED: Integration of single-cell datasets reveals novel transcriptomic signatures of ß-cells in human T2D
Abstract Pancreatic islet β-cell failure is key to the onset and progression of type 2 diabetes (T2D). The advent of single-cell RNA sequencing (scRNA-seq) has opened the possibility to...
IBRI RESEARCH PUBLISHED: Enzyme Immunoassay-Based Platform for Accurate Detection of Serum Pathological a-Synuclein in Parkinson’s Disease Patients
Abstract An assay for accurately diagnosing early stage Parkinson’s Disease (PD) is currently unavailable, and therefore, there is an urgent and unmet need. Such a diagnostic assay will enable...
IBRI IN THE NEWS: Biosciences Research Institute Adds Board Members
The Indiana Biosciences Research Institute has added eight members to its board of directors, including Bob Bernhard (pictured) and Wendy Srnic (pictured). Bernhard serves as vice president for research at...
IBRI RESEARCH PUBLISHED: YIPF5 Mutations Cause Neonatal Diabetes and Microcephaly through Endoplasmic Reticulum Stress
Abstract Neonatal diabetes is caused by single gene mutations reducing pancreatic β cell number or impairing β cell function. Understanding the genetic basis of rare diabetes subtypes highlights fundamental...